Child Health Research Centre, Faculty of Medicine, The University of Queensland, South Brisbane, QLD, Australia.
Eur J Clin Nutr. 2022 Jul;76(7):913-921. doi: 10.1038/s41430-021-01027-9. Epub 2021 Oct 21.
Manipulation of the gut microbiome offers a promising treatment option for children with autism spectrum disorder (ASD) for whom functional gastrointestinal disorders (FGIDs) are a common comorbidity. Both ASD and FGIDs have been linked to dysfunction of the microbiome-gut-brain (MGB) axis. Dysfunction of this bidirectional network has the ability to impact multiple host processes including gastrointestinal (GI) function, mood and behaviour. Prebiotic and probiotic supplementation aims to produce beneficial shifts within the gut environment, resulting in favourable changes to microbial metabolite production and gastrointestinal function. The aim of this review is to investigate the gut microbiome as a therapeutic target for children with ASD. Evidence for the utility of prebiotics, probiotics or synbiotics (i.e., prebiotic + probiotic) among this cohort is examined. Electronic databases (PubMed, Web of Science, Medline and clinicaltrials.gov) were searched using keywords or phrases to review the literature from 1 January 2010 to 30 October 2020. Findings suggest limited, but preliminary evidence of efficacy in relieving GI distress, improving ASD-associated behaviours, altering microbiota composition, and reducing inflammatory potential.
肠道微生物组的操纵为自闭症谱系障碍(ASD)儿童提供了一种有前途的治疗选择,因为功能性胃肠道疾病(FGIDs)是 ASD 的常见合并症。ASD 和 FGIDs 都与微生物组-肠道-大脑(MGB)轴的功能障碍有关。这个双向网络的功能障碍能够影响多个宿主过程,包括胃肠道(GI)功能、情绪和行为。益生元和益生菌的补充旨在产生肠道环境中的有益变化,从而导致微生物代谢产物产生和胃肠道功能的有利变化。本综述的目的是研究肠道微生物组作为 ASD 儿童的治疗靶点。研究了该队列中使用益生元、益生菌或合生元(即益生元+益生菌)的效果。使用关键词或短语在电子数据库(PubMed、Web of Science、Medline 和 clinicaltrials.gov)中进行了检索,以审查 2010 年 1 月 1 日至 2020 年 10 月 30 日的文献。研究结果表明,在缓解胃肠道不适、改善与 ASD 相关的行为、改变微生物群落组成和降低炎症潜力方面,有有限但初步的疗效证据。